Equities

StemRIM Inc

4599:TYO

StemRIM Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)472.00
  • Today's Change30.00 / 6.79%
  • Shares traded413.40k
  • 1 Year change-50.47%
  • Beta1.8620
Data delayed at least 20 minutes, as of Jul 17 2024 07:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.

  • Revenue in JPY (TTM)0.00
  • Net income in JPY-2.13bn
  • Incorporated2006
  • Employees44.00
  • Location
    StemRIM Inc3F, Saito Bio-Incubator, 7-7-15, SaitoIBARAKI-SHI 567-0085JapanJPN
  • Phone+81 726487152
  • Websitehttps://stemrim.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
RaQualia Pharma Inc2.18bn-253.40m13.81bn67.00--2.30--6.33-11.72-11.72100.79277.210.2472.763.0332,526,720.00-2.872.13-3.182.2688.7088.49-11.635.323.53--0.40310.00-34.8520.62-144.74--0.0967--
Symbio Pharmaceuticals Ltd4.64bn-2.74bn14.23bn109.00--1.98--3.07-66.88-66.88113.80156.380.54392.765.1442,594,130.00-32.15-19.18-35.33-23.6278.3865.84-59.12-24.3210.43--0.00---44.157.82-266.45--42.39--
Stella Pharma Corp269.49m-763.75m14.45bn44.00--5.70--53.63-24.63-24.638.7076.120.06610.05083.986,124,796.00-18.74-22.50-21.00-24.8380.63---283.40-488.655.52-1,319.970.2819--17.65--1.94---5.87--
Ohki Healthcare Holdings Co Ltd334.66bn2.21bn14.55bn632.006.440.50675.810.0435160.45160.4524,293.962,040.702.5613.334.80529,526,900.001.631.857.078.425.146.160.63560.71780.8922--0.199613.929.925.301.281.51-5.345.92
Fuso Pharmaceutical Industries Ltd55.41bn1.38bn22.20bn1.31k14.700.54756.200.4007159.76159.766,434.774,290.490.74743.122.4342,392,500.001.861.913.063.0924.9826.922.492.691.0454.560.257641.108.613.76-14.219.029.13-2.64
Astena Holdings Co Ltd52.63bn1.62bn23.32bn1.40k13.890.78766.060.443140.9840.981,332.61722.460.81273.312.7637,482,540.002.492.494.444.4432.2725.333.062.320.8713--0.351744.924.73-2.85100.61-3.8538.5411.38
TAIKO PHARMACEUTICAL CO LTD6.33bn-2.90bn23.50bn208.00--3.13--3.71-58.49-58.49129.20148.040.4622.043.4430,432,690.00-21.14---26.00--44.27---45.75--2.92--0.2811--21.43--26.23------
StemRIM Inc0.00-2.13bn27.19bn44.00--2.90-----34.87-34.870.00152.360.00----0.00-20.52-6.71-20.87-6.83-------45.8099.90-8,295.360.00--10,128.0663.68108.64------
CellSeed Inc193.68m-892.21m33.58bn35.00--15.00--173.38-29.71-29.716.4764.750.0881.637.625,533,600.00-40.53-49.69-43.83-54.5556.5863.66-460.67-428.6219.14--0.0669--50.39-28.62-11.43--80.73--
Daito Pharmaceutical Co Ltd46.90bn3.30bn33.74bn1.01k10.220.63126.930.7194210.18210.182,988.733,404.720.63261.892.96--4.296.275.588.2420.9822.656.788.471.11--0.14318.483.982.66-8.47-1.2711.3711.67
Fuji Pharma Co Ltd43.05bn5.92bn38.12bn1.62k6.320.84974.140.8855243.57243.571,771.381,812.380.50711.343.2126,558,910.006.974.1010.565.5839.7842.4113.757.550.5895--0.382631.1715.421.5227.410.370919.045.73
Data as of Jul 17 2024. Currency figures normalised to StemRIM Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

2.58%Per cent of shares held by top holders
HolderShares% Held
Schroder Investment Management (Japan) Ltd.as of 31 Mar 2024628.50k1.02%
Schroder Investment Management Ltd.as of 31 Dec 2023342.10k0.56%
Daiwa Asset Management Co. Ltd.as of 31 Dec 2023279.40k0.45%
Simplex Asset Management Co., Ltd.as of 04 Jul 2024167.20k0.27%
Mitsubishi UFJ Asset Management Co., Ltd.as of 31 Dec 2023109.40k0.18%
Meiji Yasuda Asset Management Co. Ltd.as of 29 Nov 202235.00k0.06%
SSgA Funds Management, Inc.as of 03 Jul 202418.60k0.03%
LGT Capital Partners AG (Investment Management)as of 30 Nov 20232.70k0.00%
Amundi Japan Ltd.as of 12 Sep 20222.00k0.00%
Connor, Clark & Lunn Investment Management Ltd.as of 31 Dec 20231.50k0.00%
More ▼
Data from 31 Mar 2024 - 11 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.